Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirtobrutinib Maintenance After CAR-T Cell Therapy in Relapsed or Refractory B-Cell Lymphoma
NCT07622784Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 2 trial of pirtobrutinib in B cell lymphoma, sponsored by Sun Yat-sen University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
pirtobrutinib
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT07622784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07622784.